(arg)9

(Arg)9 (Nona-L-arginine;Peptide R9) is a cell-penetrating peptide,and exhibits neuroprotective activity(IC50 of 0.78 μM, in the glutamic acid model).

Nona-L-arginine (Arg)9 acetate, a cell-penetrating peptide (CPP) consisting of 9 arginine residues, displays neuroprotective properties, with an IC50 of 0.78 μM in the glutamic acid model [1] [2].

(Arg)9 TFA (Peptide R9 TFA) is a cell-penetrating peptide. (Arg)9 TFA (Nona-L-arginine TFA) exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model.

Lys-[Des-Arg9]Bradykinin acetate is an endogenous potent and highly selective bradykinin B1 receptor agonist (Ki values are 0.12 and > 30000 nM at human B1 and B2 receptors respectively). Hypotensive agent that reduces peripheral vascular resistance in vivo. 16-fold more potent than [Des-Arg9]-Bradykinin.

Papain Inhibitor acetate (Gly-Gly-Tyr-Arg) is an affinity Ligand for Papain.

[Des-Arg9]-Bradykinin is an agonist of Bradykinin (B1) receptor that displays selectivity for B1 over B2 receptors.

Arg-Gly-Asp-Ser acetate is an integrin binding sequence that directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1. Arg-Gly-Asp-Ser acetate inhibits integrin receptor function.

Arg-Gly-Asp-Ser (TFA) is an integrin-binding sequence that inhibits integrin receptor function by specifically and directly binding to pro-caspase-8, pro-caspase-9, and pro-caspase-3, without interacting with pro-caspase-1 [1].

[Des-Arg9]-Bradykinin ([Des-Arg9]-Bradykinin(2TFA))(2TFA) is an agonist of Bradykinin (B1) receptor.

BRC4wt, an acetylated peptide originating from the BRC4 repeat within human BRCA2 (1521-1536), acts as an inhibitor of the BRCA2 and RAD51 protein-protein interaction. When linked to the cationic cell-penetrating peptide (Arg)9, it effectively shortens DNA replication tract lengths and diminishes the frequency of homologous repair of camptothecin-induced DNA damage in vitro. Additionally, BRC4wt enhances the efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib in inducing cell death in HeLa human cervical cancer and U2OS human osteosarcoma cells, albeit it does not affect non-cancerous hTERT RPE-1, MRC-5, or MCF-10A cells.

[Des-Arg9]-Bradykinin acetate is a selective agonist of the Bradykinin B1 receptor.

Endogenous potent and highly selective bradykinin B1 receptor agonist (Ki values are 0.12 and > 30000 nM at human B1 and B2 receptors respectively). Hypotensive agent that reduces peripheral vascular resistance in vivo. 16-fold more potent than [Des-Arg9]

Lys-[Des-Arg9]Bradykinin,TFA is Endogenous potent and highly selective bradykinin B1 receptor agonist (Ki values are 0.12 and > 30000 nM at human B1 and B2 receptors respectively). Hypotensive agent that reduces peripheral vascular resistance in vivo. 16-fold more potent than [Des-Arg9]-Bradykinin.